Clinical Trial Update: Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing Folate Receptor Alpha Peptide Vaccine with GM-CSF versus GM-CSF alone in platinum-sensitive ovarian cancer was terminated; results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Platinum-sensitive Ovarian Cancer

Drugs mentioned

• Folate receptor alpha peptide vaccine with GM-CSF
• GM-CSF (granulocyte-macrophage colony-stimulating factor)

Snippet

Sponsor: Marker Therapeutics, Inc. | Conditions: Platinum Sensitive Ovarian Cancer, Ovarian Cancer | Phase 2 | Status: TERMINATED | Results posted: 2022-12-15